These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

341 related items for PubMed ID: 16230403

  • 1. Tissue inhibitor of metalloproteinase-3 expression from an oncolytic adenovirus inhibits matrix metalloproteinase activity in vivo without affecting antitumor efficacy in malignant glioma.
    Lamfers ML, Gianni D, Tung CH, Idema S, Schagen FH, Carette JE, Quax PH, Van Beusechem VW, Vandertop WP, Dirven CM, Chiocca EA, Gerritsen WR.
    Cancer Res; 2005 Oct 15; 65(20):9398-405. PubMed ID: 16230403
    [Abstract] [Full Text] [Related]

  • 2. Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase.
    Nanda D, Vogels R, Havenga M, Avezaat CJ, Bout A, Smitt PS.
    Cancer Res; 2001 Dec 15; 61(24):8743-50. PubMed ID: 11751394
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Adenovirus carrying TIMP-3: a potential tool for cervical cancer treatment.
    Zhang Y, Qian H, Lin C, Lang J, Xiang Y, Fu M, Zhang X, Liang X.
    Gynecol Oncol; 2008 Jan 15; 108(1):234-40. PubMed ID: 17976707
    [Abstract] [Full Text] [Related]

  • 6. Differential effects of combined Ad5- delta 24RGD and radiation therapy in in vitro versus in vivo models of malignant glioma.
    Lamfers ML, Idema S, Bosscher L, Heukelom S, Moeniralm S, van der Meulen-Muileman IH, Overmeer RM, van der Valk P, van Beusechem VW, Gerritsen WR, Vandertop WP, Dirven CM.
    Clin Cancer Res; 2007 Dec 15; 13(24):7451-8. PubMed ID: 18094429
    [Abstract] [Full Text] [Related]

  • 7. A survivin-mediated oncolytic adenovirus induces non-apoptotic cell death in lung cancer cells and shows antitumoral potential in vivo.
    Li B, Liu X, Fan J, Qi R, Bo L, Gu J, Qian Q, Qian C, Liu X.
    J Gene Med; 2006 Oct 15; 8(10):1232-42. PubMed ID: 16900558
    [Abstract] [Full Text] [Related]

  • 8. An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors: dependence on E1A, the E2F-1 promoter, and viral replication for selectivity and efficacy.
    Jakubczak JL, Ryan P, Gorziglia M, Clarke L, Hawkins LK, Hay C, Huang Y, Kaloss M, Marinov A, Phipps S, Pinkstaff A, Shirley P, Skripchenko Y, Stewart D, Forry-Schaudies S, Hallenbeck PL.
    Cancer Res; 2003 Apr 01; 63(7):1490-9. PubMed ID: 12670895
    [Abstract] [Full Text] [Related]

  • 9. A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes.
    Hu ZB, Wu CT, Wang H, Zhang QW, Wang L, Wang RL, Lu ZZ, Wang LS.
    Cancer Gene Ther; 2008 Mar 01; 15(3):173-82. PubMed ID: 18157145
    [Abstract] [Full Text] [Related]

  • 10. Linked tumor-selective virus replication and transgene expression from E3-containing oncolytic adenoviruses.
    Zhu M, Bristol JA, Xie Y, Mina M, Ji H, Forry-Schaudies S, Ennist DL.
    J Virol; 2005 May 01; 79(9):5455-65. PubMed ID: 15827160
    [Abstract] [Full Text] [Related]

  • 11. A capsid-modified, conditionally replicating oncolytic adenovirus vector expressing TRAIL Leads to enhanced cancer cell killing in human glioblastoma models.
    Wohlfahrt ME, Beard BC, Lieber A, Kiem HP.
    Cancer Res; 2007 Sep 15; 67(18):8783-90. PubMed ID: 17875719
    [Abstract] [Full Text] [Related]

  • 12. ICOVIR-5 shows E2F1 addiction and potent antiglioma effect in vivo.
    Alonso MM, Cascallo M, Gomez-Manzano C, Jiang H, Bekele BN, Perez-Gimenez A, Lang FF, Piao Y, Alemany R, Fueyo J.
    Cancer Res; 2007 Sep 01; 67(17):8255-63. PubMed ID: 17804740
    [Abstract] [Full Text] [Related]

  • 13. Expression of p53, or targeting towards EGFR, enhances the oncolytic potency of conditionally replicative adenovirus against neuroblastoma.
    Geoerger B, van Beusechem VW, Opolon P, Morizet J, Laudani L, Lecluse Y, Barrois M, Idema S, Grill J, Gerritsen WR, Vassal G.
    J Gene Med; 2005 May 01; 7(5):584-94. PubMed ID: 15651070
    [Abstract] [Full Text] [Related]

  • 14. Efficacy of systemically administered oncolytic vaccinia virotherapy for malignant gliomas is enhanced by combination therapy with rapamycin or cyclophosphamide.
    Lun XQ, Jang JH, Tang N, Deng H, Head R, Bell JC, Stojdl DF, Nutt CL, Senger DL, Forsyth PA, McCart JA.
    Clin Cancer Res; 2009 Apr 15; 15(8):2777-88. PubMed ID: 19351762
    [Abstract] [Full Text] [Related]

  • 15. Oncolytic activity of the E1B-55 kDa-deleted adenovirus ONYX-015 is independent of cellular p53 status in human malignant glioma xenografts.
    Geoerger B, Grill J, Opolon P, Morizet J, Aubert G, Terrier-Lacombe MJ, Bressac De-Paillerets B, Barrois M, Feunteun J, Kirn DH, Vassal G.
    Cancer Res; 2002 Feb 01; 62(3):764-72. PubMed ID: 11830531
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.